Andreas Engert

37.0k total citations · 4 hit papers
552 papers, 20.7k citations indexed

About

Andreas Engert is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andreas Engert has authored 552 papers receiving a total of 20.7k indexed citations (citations by other indexed papers that have themselves been cited), including 402 papers in Pathology and Forensic Medicine, 204 papers in Oncology and 185 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andreas Engert's work include Lymphoma Diagnosis and Treatment (399 papers), Lung Cancer Treatments and Mutations (169 papers) and Chronic Lymphocytic Leukemia Research (100 papers). Andreas Engert is often cited by papers focused on Lymphoma Diagnosis and Treatment (399 papers), Lung Cancer Treatments and Mutations (169 papers) and Chronic Lymphocytic Leukemia Research (100 papers). Andreas Engert collaborates with scholars based in Germany, United States and Switzerland. Andreas Engert's co-authors include Volker Diehl, Peter Borchmann, Dennis A. Eichenauer, Andreas Josting, Bastian von Tresckow, H. Schulz, Julia Bohlius, Michael Fuchs, Nicole Skoetz and Thomas Elter and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Andreas Engert

529 papers receiving 20.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

2012 1.0k citations Anas Younes, Ajay K. Gopal et al. Journal of Clinical Oncology profile →
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

1999 516 citations H. Schulz, Volker Diehl et al. Blood profile →
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

2018 455 citations Philippe Armand, Andreas Engert et al. Journal of Clinical Oncology profile →
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2014 324 citations Dennis A. Eichenauer, Andreas Engert et al. profile →

Peers

Countries citing papers authored by Andreas Engert

Since Specialization

Citations

This map shows the geographic impact of Andreas Engert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Engert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Engert more than expected).

Fields of papers citing papers by Andreas Engert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Engert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Engert. The network helps show where Andreas Engert may publish in the future.

Co-authorship network of co-authors of Andreas Engert

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Engert. A scholar is included among the top collaborators of Andreas Engert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Engert. Andreas Engert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Role of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial 2022 ·Nuklearmedizin - NuclearMedicine ·(unknown), (unknown), (unknown), Jasmin Mettler, Felicitas Hitz, Christian Baues, Michael Fuchs, Peter Borchmann, Andreas Engert, Markus Dietlein, Conrad‐Amadeus Voltin, Carsten Kobe	1
2	Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial 2021 ·International Journal of Radiation OncologyBiologyPhysics ·Christian Baues, Helen Goergen, Michael Fuchs, Johannes Rosenbrock, Eren Celik, Hans Theodor Eich, Carsten Kobe, Conrad‐Amadeus Voltin, Andreas Engert, Peter Borchmann, Simone Marnitz	6
3	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial breakdown → 2018 ·Journal of Clinical Oncology ·Philippe Armand, Andreas Engert, Anas Younes, Michelle A. Fanale, Armando Santoro, Pier Luigi Zinzani, John M. Timmerman, Graham P. Collins, Radhakrishnan Ramchandren, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Margaret A. Shipp, Kazunobu Kato, Anne Sumbul, Benedetto Farsaci, Stephen M. Ansell	455
4	Clinical Outcomes of Patients with 3rd or Higher Relapsed Classical Hodgkin Lymphoma: Results from the German Hodgkin Study Group 2017 ·Blood ·(unknown), Horst Mueller, (unknown), Peter Kaskel, (unknown), Hilde Giezek, Arun Balakumaran, Monika Raut, Andreas Engert, Bastian von Tresckow	1
5	An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma 2015 ·Clinical Cancer Research ·Bastian von Tresckow, Franck Morschhauser, Vincent Ribrag, Max S. Topp, Caly Chien, Shobha Seetharam, (unknown), (unknown), Carla J. de Boer, Andreas Engert	94
6	Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group 2015 ·Leukemia & lymphoma ·Stephanie Sasse, (unknown), Horst Müller, Lenka Šmardová, Bernd Metzner, Hartmut Doehner, Thomas Fischer, Dietger Niederwieser, Norbert Schmitz, Kerstin Schäfer‐Eckart, John Raemaekers, Oliver Schmalz, Bastian von Tresckow, Andreas Engert, Peter Borchmann	9
7	The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG) 2013 ·Blood ·Sylvia Hartmann, Dennis A. Eichenauer, Annette Plütschow, Anja Mottok, Roshanak Bob, Karoline Koch, Heinz‐Wolfram Bernd, Sergio Cogliatti, Michael Hummel, Alfred C. Feller, German Ott, Peter Mӧller, Andreas Rosenwald, Harald Stein, Martin‐Leo Hansmann, Andreas Engert, Wolfram Klapper	112
8	The German evidence-based guidelines for Hodgkin’s lymphoma 2013 ·Strahlentherapie und Onkologie ·Hans Theodor Eich, (unknown), Heinz Schmidberger, Boris Böll, Beate Klimm, Michaela Rancea, R.-P. Müller, Andreas Engert	3
9	Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience 2012 ·Blood ·Achim Rothe, Stephanie Sasse, Helen Goergen, Dennis A. Eichenauer, Andreas Lohri, Ulrich Jäger, Christopher Bangard, Boris Böll, (unknown), Sebastian Theurich, Peter Borchmann, Andreas Engert	60
10	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma breakdown → 2012 ·Journal of Clinical Oncology ·Anas Younes, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, Kerry J. Savage, Radhakrishnan Ramchandren, Nancy L. Bartlett, Bruce D. Cheson, Sven de Vos, Andres Forero‐Torres, Craig H. Moskowitz, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Dana A. Kennedy, Eric L. Sievers, Robert Chen	1014
11	Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL) 2012 ·Cochrane Database of Systematic Reviews ·(unknown), Ina Monsef, Gerald Illerhaus, Andreas Engert, Nicole Skoetz	24
12	Thirteenth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Multiple Myeloma 2011 ·JNCI Journal of the National Cancer Institute ·K. H. Bauer, Michaela Rancea, (unknown), Sabine Kluge, Ina Monsef, Kai Hübel, Andreas Engert, Nicole Skoetz	4
13	Efficacy of panobinostat in phase II study in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant 2010 ·British Journal of Haematology ·John Radford, Andrew Davies, Martin J.S. Dyer, Anna Sureda, Andreas Engert, Angela Shen, Samit Hirawat, Anas Younes	1
14	Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study 2009 ·Journal of Clinical Oncology ·Andreas Engert, Volker Diehl, Jeremy Franklin, Andreas Lohri, Bernd Dörken, Wolf‐Dieter Ludwig, P. Koch, Mathias Hänel, Michael Pfreundschuh, Martin Wilhelm, Lorenz Trümper, (unknown), Martin Bentz, Mathias Rummel, Orhan Sezer, Hans–Konrad Müller–Hermelink, Dirk Hasenclever, Markus Löffler	303
15	HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL SUPPORT IN FIRST LINE TREATMENT OF AGGRESSIVE NON HODGKIN LYMPHOMA: RESULTS OF AN INDIVIDUAL PATIENT DATA META-ANALYSIS 2009 ·IRIS Research product catalog (Sapienza University of Rome) ·Corinne Brillant, Guido Schwarzer, Julia Bohlius, (unknown), Sven Trelle, Corinne Haïoun, André De Souza, Christian Gisselbrecht, Tanin Intragumtornchai, Ulrich Kaiser, (unknown), Maurizio Martelli, Nöel Milpied, (unknown), Umberto Vitolo, Andreas Engert, H. Schulz	1
16	Dendritic Cells Release HLA-B-Associated Transcript-3 Positive Exosomes to Regulate Natural Killer Function 2008 ·PLoS ONE ·Venkateswara R. Simhadri, Katrin S. Reiners, Hinrich P. Hansen, (unknown), Vijaya L. Simhadri, Klaus Nohroudi, Thomas A. Kufer, Andreas Engert, Elke Pogge von Strandmann	217
17	Lymphocyte‐predominant and classical Hodgkin's lymphoma – comparison of outcomes 2005 ·European Journal Of Haematology ·(unknown), Thorsten Reineke, Andreas Josting, Hans Konrad Müller‐Hermelink, Hans Theodor Eich, Karolin Behringer, Rolf‐Peter Müller, Volker Diehl, Andreas Engert	20
18	Biophysical analysis of acute toxicity of radiotherapy in Hodgkin’s lymphoma — a comparison between extended field and involved field radiotherapy based on the data of the german hodgkin study group (GHSG) 2004 ·International Journal of Radiation OncologyBiologyPhysics ·Hans‐Theodor Eich, Uwe Haverkamp, Andreas Engert, Martin Köcher, (unknown), (unknown), (unknown), Volker Diehl, R.P. Mueller	0
19	Depletion of Cellular Cholesterol and Lipid Rafts Increases Shedding of CD30 2004 ·The Journal of Immunology ·Bastian von Tresckow, Karl‐Josef Kallen, Elke Pogge von Strandmann, Peter Borchmann, Hans Lange, Andreas Engert, Hinrich P. Hansen	93
20	Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia 2002 ·Annals of Hematology ·(unknown), Marcel Reiser, Stefan Barth, Peter Borchmann, H. Schulz, (unknown), (unknown), J. Wessels, (unknown), Volker Diehl, Andreas Engert	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact